Differential effects of aspirin and non-aspirin nonsteroidal antiinflammatory drugs in the primary prevention of myocardial infarction in postmenopausal women. García Rodríguez, L. A., Varas, C., & Patrono, C. Epidemiology (Cambridge, Mass.), 11(4):382--387, July, 2000. abstract bibtex The antiplatelet effect of aspirin reduces the risk of clinical manifestations of atherothrombosis by approximately 25% in secondary prevention settings. Data are limited in primary prevention of coronary heart disease, and even more in women. Here, we estimate the effects of aspirin and non-aspirin nonsteroidal antiinflammatory drugs in the primary prevention of myocardial infarction in postmenopausal women. We followed a cohort of 164,769 women, 50-74 years of age, registered in the General Practice Research Database in the United Kingdom, from January 1991 through December 1995. For aspirin and non-aspirin nonsteroidal antiinflammatory drugs, the risk of myocardial infarction associated with current use was compared with risk in non-users, using a nested case-control analysis. Overall, the relative risk of myocardial infarction associated with current use of aspirin of more than 1 month's duration was 0.56 [95% confidence interval (95% CI) = 0.26-1.21], and that of nonfatal myocardial infarction was 0.28 (95% CI = 0.08-0.91). Chronic use of nonsteroidal antiinflammatory drugs was not associated with a protective effect (relative risk = 1.32; 95% CI = 0.97-1.81). These findings indicate that incomplete and reversible inhibition of platelet cyclooxygenase by non-aspirin nonsteroidal antiinflammatory drugs is not sufficient to produce clinically detectable cardiovascular protection comparable with that achieved by low-dose aspirin through irreversible inactivation of platelet cyclooxygenase.
@article{garcia_rodriguez_differential_2000,
title = {Differential effects of aspirin and non-aspirin nonsteroidal antiinflammatory drugs in the primary prevention of myocardial infarction in postmenopausal women},
volume = {11},
issn = {1044-3983},
abstract = {The antiplatelet effect of aspirin reduces the risk of clinical manifestations of atherothrombosis by approximately 25\% in secondary prevention settings. Data are limited in primary prevention of coronary heart disease, and even more in women. Here, we estimate the effects of aspirin and non-aspirin nonsteroidal antiinflammatory drugs in the primary prevention of myocardial infarction in postmenopausal women. We followed a cohort of 164,769 women, 50-74 years of age, registered in the General Practice Research Database in the United Kingdom, from January 1991 through December 1995. For aspirin and non-aspirin nonsteroidal antiinflammatory drugs, the risk of myocardial infarction associated with current use was compared with risk in non-users, using a nested case-control analysis. Overall, the relative risk of myocardial infarction associated with current use of aspirin of more than 1 month's duration was 0.56 [95\% confidence interval (95\% CI) = 0.26-1.21], and that of nonfatal myocardial infarction was 0.28 (95\% CI = 0.08-0.91). Chronic use of nonsteroidal antiinflammatory drugs was not associated with a protective effect (relative risk = 1.32; 95\% CI = 0.97-1.81). These findings indicate that incomplete and reversible inhibition of platelet cyclooxygenase by non-aspirin nonsteroidal antiinflammatory drugs is not sufficient to produce clinically detectable cardiovascular protection comparable with that achieved by low-dose aspirin through irreversible inactivation of platelet cyclooxygenase.},
language = {eng},
number = {4},
journal = {Epidemiology (Cambridge, Mass.)},
author = {García Rodríguez, L. A. and Varas, C. and Patrono, C.},
month = jul,
year = {2000},
pmid = {10874543},
keywords = {Age Factors, Aged, Anti-Inflammatory Agents, Non-Steroidal, Aspirin, Cohort Studies, Female, Humans, Middle Aged, Myocardial Infarction, PREVENTIVE MEDICINE, Postmenopause, incidence},
pages = {382--387}
}
Downloads: 0
{"_id":"q9WtDDQ3m4abZPtvx","bibbaseid":"garcarodrguez-varas-patrono-differentialeffectsofaspirinandnonaspirinnonsteroidalantiinflammatorydrugsintheprimarypreventionofmyocardialinfarctioninpostmenopausalwomen-2000","downloads":0,"creationDate":"2017-08-15T09:38:10.547Z","title":"Differential effects of aspirin and non-aspirin nonsteroidal antiinflammatory drugs in the primary prevention of myocardial infarction in postmenopausal women","author_short":["García Rodríguez, L. A.","Varas, C.","Patrono, C."],"year":2000,"bibtype":"article","biburl":"http://bibbase.org/zotero/veegee78","bibdata":{"bibtype":"article","type":"article","title":"Differential effects of aspirin and non-aspirin nonsteroidal antiinflammatory drugs in the primary prevention of myocardial infarction in postmenopausal women","volume":"11","issn":"1044-3983","abstract":"The antiplatelet effect of aspirin reduces the risk of clinical manifestations of atherothrombosis by approximately 25% in secondary prevention settings. Data are limited in primary prevention of coronary heart disease, and even more in women. Here, we estimate the effects of aspirin and non-aspirin nonsteroidal antiinflammatory drugs in the primary prevention of myocardial infarction in postmenopausal women. We followed a cohort of 164,769 women, 50-74 years of age, registered in the General Practice Research Database in the United Kingdom, from January 1991 through December 1995. For aspirin and non-aspirin nonsteroidal antiinflammatory drugs, the risk of myocardial infarction associated with current use was compared with risk in non-users, using a nested case-control analysis. Overall, the relative risk of myocardial infarction associated with current use of aspirin of more than 1 month's duration was 0.56 [95% confidence interval (95% CI) = 0.26-1.21], and that of nonfatal myocardial infarction was 0.28 (95% CI = 0.08-0.91). Chronic use of nonsteroidal antiinflammatory drugs was not associated with a protective effect (relative risk = 1.32; 95% CI = 0.97-1.81). These findings indicate that incomplete and reversible inhibition of platelet cyclooxygenase by non-aspirin nonsteroidal antiinflammatory drugs is not sufficient to produce clinically detectable cardiovascular protection comparable with that achieved by low-dose aspirin through irreversible inactivation of platelet cyclooxygenase.","language":"eng","number":"4","journal":"Epidemiology (Cambridge, Mass.)","author":[{"propositions":[],"lastnames":["García","Rodríguez"],"firstnames":["L.","A."],"suffixes":[]},{"propositions":[],"lastnames":["Varas"],"firstnames":["C."],"suffixes":[]},{"propositions":[],"lastnames":["Patrono"],"firstnames":["C."],"suffixes":[]}],"month":"July","year":"2000","pmid":"10874543","keywords":"Age Factors, Aged, Anti-Inflammatory Agents, Non-Steroidal, Aspirin, Cohort Studies, Female, Humans, Middle Aged, Myocardial Infarction, PREVENTIVE MEDICINE, Postmenopause, incidence","pages":"382--387","bibtex":"@article{garcia_rodriguez_differential_2000,\n\ttitle = {Differential effects of aspirin and non-aspirin nonsteroidal antiinflammatory drugs in the primary prevention of myocardial infarction in postmenopausal women},\n\tvolume = {11},\n\tissn = {1044-3983},\n\tabstract = {The antiplatelet effect of aspirin reduces the risk of clinical manifestations of atherothrombosis by approximately 25\\% in secondary prevention settings. Data are limited in primary prevention of coronary heart disease, and even more in women. Here, we estimate the effects of aspirin and non-aspirin nonsteroidal antiinflammatory drugs in the primary prevention of myocardial infarction in postmenopausal women. We followed a cohort of 164,769 women, 50-74 years of age, registered in the General Practice Research Database in the United Kingdom, from January 1991 through December 1995. For aspirin and non-aspirin nonsteroidal antiinflammatory drugs, the risk of myocardial infarction associated with current use was compared with risk in non-users, using a nested case-control analysis. Overall, the relative risk of myocardial infarction associated with current use of aspirin of more than 1 month's duration was 0.56 [95\\% confidence interval (95\\% CI) = 0.26-1.21], and that of nonfatal myocardial infarction was 0.28 (95\\% CI = 0.08-0.91). Chronic use of nonsteroidal antiinflammatory drugs was not associated with a protective effect (relative risk = 1.32; 95\\% CI = 0.97-1.81). These findings indicate that incomplete and reversible inhibition of platelet cyclooxygenase by non-aspirin nonsteroidal antiinflammatory drugs is not sufficient to produce clinically detectable cardiovascular protection comparable with that achieved by low-dose aspirin through irreversible inactivation of platelet cyclooxygenase.},\n\tlanguage = {eng},\n\tnumber = {4},\n\tjournal = {Epidemiology (Cambridge, Mass.)},\n\tauthor = {García Rodríguez, L. A. and Varas, C. and Patrono, C.},\n\tmonth = jul,\n\tyear = {2000},\n\tpmid = {10874543},\n\tkeywords = {Age Factors, Aged, Anti-Inflammatory Agents, Non-Steroidal, Aspirin, Cohort Studies, Female, Humans, Middle Aged, Myocardial Infarction, PREVENTIVE MEDICINE, Postmenopause, incidence},\n\tpages = {382--387}\n}\n\n","author_short":["García Rodríguez, L. A.","Varas, C.","Patrono, C."],"key":"garcia_rodriguez_differential_2000","id":"garcia_rodriguez_differential_2000","bibbaseid":"garcarodrguez-varas-patrono-differentialeffectsofaspirinandnonaspirinnonsteroidalantiinflammatorydrugsintheprimarypreventionofmyocardialinfarctioninpostmenopausalwomen-2000","role":"author","urls":{},"keyword":["Age Factors","Aged","Anti-Inflammatory Agents","Non-Steroidal","Aspirin","Cohort Studies","Female","Humans","Middle Aged","Myocardial Infarction","PREVENTIVE MEDICINE","Postmenopause","incidence"],"downloads":0},"search_terms":["differential","effects","aspirin","non","aspirin","nonsteroidal","antiinflammatory","drugs","primary","prevention","myocardial","infarction","postmenopausal","women","garcía rodríguez","varas","patrono"],"keywords":["age factors","aged","anti-inflammatory agents","non-steroidal","aspirin","cohort studies","female","humans","middle aged","myocardial infarction","preventive medicine","postmenopause","incidence"],"authorIDs":[],"dataSources":["FmCWXwJibZiWNzpdc"]}